View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 13, 2020updated 04 Sep 2020 8:14am

Vir Biotechnology discovers two antibodies against new coronavirus

US-based immunology company Vir Biotechnology has identified two monoclonal antibodies (mAbs) that can bind to the new coronavirus, 2019-nCoV or SARS-CoV-2.

Follow the latest updates of the outbreak on our timeline.

US-based immunology company Vir Biotechnology has identified two monoclonal antibodies (mAbs) that can bind to the new coronavirus, 2019-nCoV or SARS-CoV-2.

The company discovered the antibodies from an existing library of 20 fully human antibodies, which bind and neutralise certain coronaviruses.

Researchers formerly identified these coronavirus antibodies to attach to and neutralise SARS coronavirus (SARS-CoV).

The company notes that the antibodies act on the SARS-CoV-2 spike protein present in the region used by the virus to enter cells via the cellular receptor ACE2.

Infection caused by the new coronavirus has been officially named Covid-19.

Vir Biotechnology CEO George Scangos said: “We are in the process of assessing neutralisation with a pseudo-virus. In addition, we are working with international partners to assess the capacity of these antibodies to neutralise the live virus, SARS-CoV-2.”

The company is exploring if these mAbs, or other antibodies identified, can offer effective treatment or prophylaxis against the virus.

Vir intends to form alliances with companies and governmental agencies to support its research and to access manufacturing capacity worldwide.

Vir Biotechnology chief scientific officer Herbert Virgin said: “We are pleased that, using the same platform that was used to isolate mAb114, which has proven to be active against Ebola, we have quickly identified antibodies with potential biological activity against SARS-CoV-2.”

According to the company, antibodies can be both therapeutic and prophylactic, while vaccines provide only protection.

An antibody delivers an immune response that becomes effective within hours of injection, while vaccine involves making of an immune response by an individual and takes weeks.

Last month, Vir announced that the company is using different platforms to determine if its previously identified mAbs against coronavirus can bind and neutralise the virus.

The company is using its antibody technology platform to isolate new antibodies specific for SARS-CoV-2.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology